May 22, 2020 — 
The investment announced this week comes just as Oxford’s vaccine team enters a crucial phase in its human trials: expanding testing with the enrollment of more than 10,000 people, including children age 5 to 12, and people over 70.
The investment announced this week comes just as Oxford’s vaccine team enters a crucial phase in its human trials: expanding testing with the enrollment of more than 10,000 people, including children age 5 to 12, and people over 70. ###
